A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

ClinicalTrials.gov ID: NCT06564038

Public ClinicalTrials.gov record NCT06564038. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Study identification

NCT ID: NCT06564038
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 408 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 29, 2025
Primary completion: Jun 10, 2029
Completion: Jun 10, 2029
Last update posted: Aug 11, 2026

2025 – 2029

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 11

Facility	City	State	ZIP	Site status
Research Site	Boston	Massachusetts	02215	Recruiting
Research Site	Hackensack	New Jersey	07601	Recruiting
Research Site	New Brunswick	New Jersey	08901	Recruiting
Research Site	New York	New York	10029	Recruiting
Research Site	New York	New York	10065	Withdrawn
Research Site	Charlotte	North Carolina	28204	Not yet recruiting
Research Site	Columbus	Ohio	43210	Recruiting
Research Site	Portland	Oregon	97239	Recruiting
Research Site	Philadelphia	Pennsylvania	19104	Recruiting
Research Site	Pittsburgh	Pennsylvania	15232	Recruiting
Research Site	Providence	Rhode Island	02903	Recruiting
Research Site	Houston	Texas	77030	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06564038, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06564038 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →